Literature DB >> 17564750

Development and trends of surgical modalities for breast cancer in China: a review of 16-year data.

Ke-Da Yu1, Gen-Hong Di, Jiong Wu, Jin-Song Lu, Kun-Wei Shen, Zhen-Zhou Shen, Zhi-Min Shao.   

Abstract

BACKGROUND: Surgery is the most important treatment for nonmetastatic breast cancer; however, the utilization of modern surgical techniques in management of breast cancer in mainland China has not been reported.
METHODS: The medical records of 5887 consecutive breast cancer patients treated surgically in the past 16 years were reviewed retrospectively; the utilization of different surgical modalities and associated clinical outcomes were analyzed.
RESULTS: Median age of all patients was 50 (range 16-92). About 1015 patients were staged as 0-I, 3569 stage II, 517 stage III, and 786 cases could not be staged. Extensive radical mastectomy (ERM), radical mastectomy (RM), modified radical mastectomy (MRM), simple mastectomy (SM), and breast-conserving surgery (BCS) were used in 8%, 27.2%, 55.7%, 1.5%, and 6.3% of patients, respectively. In addition, 1.3% of patients received breast reconstruction. The proportion of early-stage breast cancer increased, and the surgery patterns varied. MRM gradually replaced ERM and RM. The prevalence of BCS began to increase from the mid-1990s and currently represents about 12%. The prevalence of reconstruction also increased and now accounts for 5%. Age, pathologic pattern, and TNM staging affected the choice of surgery modalities markedly. Although patients receiving RM/ERM had worse survival than those receiving BCS/MRM, the survival outcomes of these four groups were similar in the early-stage population.
CONCLUSIONS: MRM remains the most-used surgical modality in operable breast cancer, although the utilization of BCS for early-stage disease has increased rapidly in last decade. Reconstruction following mastectomy as an alternative to BCS is available. Breast-conserving therapy (BCT) and MRM provide similar local controls and long-term survival for breast cancer. Selection of appropriate candidates for a certain surgery requires an assessment of the patient's age and clinical and pathological characteristics of the tumor.

Entities:  

Mesh:

Year:  2007        PMID: 17564750     DOI: 10.1245/s10434-007-9436-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

Review 1.  Breast reconstruction after mastectomy for breast cancer.

Authors:  Jennica Platt; Nancy Baxter; Toni Zhong
Journal:  CMAJ       Date:  2011-11-07       Impact factor: 8.262

2.  Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis.

Authors:  Feng Wang; Lixin Jiang; Jianlin Li; Xiao Yu; Mingchuan Li; Guochang Wu; Zhenyu Yu; Kai Zhou; Haidi Chu; Huiyuan Zhai
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Breast reconstruction rate and profile in a Singapore patient population: a National University Hospital experience.

Authors:  Nadia Sim; Sharon Soh; Chuan Han Ang; Chor Hoong Hing; Han Jing Lee; Vigneswaran Nallathamby; Yan Lin Yap; Wei Chen Ong; Thiam Chye Lim; Jane Lim
Journal:  Singapore Med J       Date:  2017-05-15       Impact factor: 1.858

Review 4.  Current Status and Future Projections of Breast Cancer in Asia.

Authors:  Lei Fan; Paul E Goss; Kathrin Strasser-Weippl
Journal:  Breast Care (Basel)       Date:  2015-12-15       Impact factor: 2.860

5.  Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery.

Authors:  Ke-Da Yu; Shuang Li; Zhi-Ming Shao
Journal:  Oncologist       Date:  2011-06-16

6.  International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.

Authors:  John Semple; Kelly A Metcalfe; Henry T Lynch; Charmaine Kim-Sing; Leigha Senter; Tuya Pal; Peter Ainsworth; Jan Lubinski; Nadine Tung; Charis Eng; Donna Gilchrist; Joanne Blum; Susan L Neuhausen; Christian F Singer; Parviz Ghadirian; Ping Sun; Steven A Narod
Journal:  Ann Surg Oncol       Date:  2013-06-06       Impact factor: 5.344

7.  Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.

Authors:  Xiao-Hua Zeng; Zhou-Luo Ou; Ke-Da Yu; Lan-Yun Feng; Wen-Jing Yin; Jing Li; Zhen-Zhou Shen; Zhi-Min Shao
Journal:  Med Oncol       Date:  2014-08-06       Impact factor: 3.064

8.  A straightforward but not piecewise relationship between age and lymph node status in Chinese breast cancer patients.

Authors:  Ke-Da Yu; Jun-Jie Li; Gen-Hong Di; Jiong Wu; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

Review 9.  CYP2D6 and tamoxifen: DNA matters in breast cancer.

Authors:  Janelle M Hoskins; Lisa A Carey; Howard L McLeod
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

10.  Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Authors:  Ke-da Yu; Gen-hong Di; Jiong Wu; Jin-song Lu; Kun-wei Shen; Guang-yu Liu; Zhen-zhou Shen; Zhio-ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.